Saturday 17 October 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.3%, EPS grew 40.7% and free cash flow grew 33.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.03
0.04
−3.74%
Follow LSTA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Altman Z-Score |
(43.85) | (20.39) | — | — | — | — | — | — | — | — |
P/S ratio |
1.06 | 0.93 | — | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(100.35) | (44.50) | — | — | — | — | — | — | — | — |
P/Operating CF |
(4.97) | (5.48) | — | — | — | — | — | — | — | — |
P/B ratio |
1.11 | 0.85 | — | — | — | — | — | — | — | — |
Price to Tangible BV |
1.12 | 0.85 | — | — | — | — | — | — | — | — |
EV/Sales |
0.22 | (0.12) | — | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.14 | — | — | — | — | — | — | — | — |
EV/Operating CF |
(0.21) | 0.17 | — | — | — | — | — | — | — | — |
EV/FCF |
(0.21) | 0.16 | — | — | — | — | — | — | — | — |
Quick Ratio |
5.20 | 5.73 | 7.67 | 10.85 | 21.00 | 9.86 | 4.21 | 7.66 | 6.45 | 0.34 |
Current Ratio |
5.76 | 6.16 | 8.18 | 11.26 | 21.27 | 10.08 | 4.35 | 7.85 | 6.59 | 1.16 |
Net Debt/EBITDA |
0.88 | 1.38 | 1.91 | 1.22 | 3.59 | 1.84 | 1.27 | 2.61 | 2.24 | 0.04 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.86% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.43 |
Asset Turnover |
0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.96 | 0.97 | 0.96 | 0.39 | 0.81 | 1.08 | 0.98 | 1.24 | (0.91) | 0.72 |
Capex/Depreciation |
(0.39) | 0.00 | 0.00 | (0.33) | (0.02) | (0.05) | 0.00 | (0.26) | (0.19) | (2.44) |
Interest Coverage |
— | — | — | (54.75) | (192.38) | (145.04) | (27.15) | (3,397.40) | (73.00) | (16.58) |
| (75.53%) | (51.77%) | (36.49%) | (68.50%) | (44.21%) | (30.87%) | (66.75%) | (36.89%) | 84.71% | (238.80%) | |
| (62.89%) | (44.56%) | (32.63%) | (63.78%) | (41.30%) | (25.81%) | (53.98%) | (29.95%) | 39.32% | (58.99%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (658.43%) |
Return on Tangible Assets |
(113.22%) | (68.83%) | (43.87%) | (82.42%) | (29.95%) | (25.56%) | (96.34%) | (41.83%) | 43.90% | (782.84%) |
Average Days of Receivables |
0.00 | 328.50 | — | — | — | — | — | — | — | 0.00 |
Research and Development Expense of Revenue |
4,675.88% | 1,133.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
6,135.29% | 1,207.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
721.18% | 165.30% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.90 | 1.16 | — | — | — | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Earnings Yield |
(102.69%) | (80.54%) | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(98.88%) | (79.13%) | — | — | — | — | — | — | — | — |
Revenue per Share |
0.02 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.84) | (2.32) | (2.48) | (4.09) | (6.03) | (8.57) | (27.42) | (30.92) | (34.90) | (54.18) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.05) | (0.02) | (0.02) | 0.00 | (0.21) | (0.23) | (2.52) |
Free Cash Flow per Share |
(1.84) | (2.32) | (2.48) | (4.14) | (6.05) | (8.59) | (27.42) | (31.13) | (35.12) | (56.70) |
Cash per Share |
1.84 | 3.75 | 6.26 | 13.36 | 25.75 | 33.57 | 36.53 | 66.61 | 100.44 | 16.20 |
Shareholders Equity per Share |
1.68 | 3.52 | 5.93 | 12.80 | 24.95 | 31.31 | 29.84 | 57.95 | 83.90 | 9.31 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.68 | 3.52 | 5.93 | 12.80 | 24.95 | 31.31 | 29.84 | 57.95 | 83.90 | 9.31 |
Free Cash Flow |
(15.98) | (19.36) | (20.03) | (21.45) | (22.30) | (8.84) | (18.88) | (20.12) | (21.01) | (24.77) |
Working Capital |
14.63 | 28.97 | 47.33 | 65.49 | 91.66 | 31.83 | 20.00 | 38.49 | 52.08 | 3.47 |
Capital Expenditures |
(0.03) | — | — | (0.28) | (0.06) | (0.02) | — | (0.13) | (0.13) | (1.10) |
Net Current Asset Value |
14.56 | 28.89 | 47.12 | 65.17 | 91.17 | 31.57 | 19.37 | 36.98 | 48.21 | (24.80) |
EV/EBIT |
0.00 | 0.14 | — | — | — | — | — | — | — | — |
Capex to Sales |
0.16 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.94 | (3.90) | (4.41) | 2.90 | 41.44 | 6.49 | 2.97 | 3.07 | 2.77 | 0.64 |
Cash ROIC |
(52.29%) | (31.96%) | (20.35%) | (15.83%) | (11.93%) | (13.24%) | (41.31%) | (24.99%) | (19.05%) | (146.09%) |
Accounts Receivable Turnover |
0.00 | 1.93 | — | — | — | — | — | — | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.52 | — | — | — | — | — | — | — | 1.35 |
Average Payables |
1.15 | 1.85 | 2.54 | 2.29 | 1.48 | 1.26 | 1.13 | 1.05 | 1.78 | 3.17 |
Average Assets |
26.37 | 44.85 | 63.86 | 85.02 | 66.51 | 31.58 | 35.87 | 53.98 | 58.45 | 55.36 |
Average Common Equity |
21.96 | 38.61 | 57.11 | 79.16 | 62.12 | 26.40 | 29.00 | 43.82 | 27.13 | 13.68 |
Columns are period end dates